Spectral Diagnostic's loss nearly triples:
This article was originally published in Clinica
Executive Summary
Canadian cardiac diagnostics developer Spectral Diagnostics has nearly tripled its loss in fiscal 1995. In the 12 months ended March its net loss rose to Can$9 million ($6.6 million) compared with Can$3.4 million in the previous year. In the same period revenues more than doubled to Can$458,000. Spectral's marketing partner for North and South America, Dade International, has begun to sell the stratus cardiac troponin I test for the evaluation of chest pain, describing it as the first whole blood, point-of-care test for cardiac markers.